Malmö, November 14, 2019 Acarix finalized a rights issue to finance further market expansion In September we announced a rights issue in order to be able to further develop our product offering and to intensify our international investments. Dur...

Press release Malmö, 30 October 2019 Inside informationAcarix AB Acarix announce final outcome in rights issue Acarix AB ("Acarix" or the "Company") has completed the new share issue of a maximum of 34,541,0...

Press release Malmö, 9 October 2019 The subscription period in Acarix' rights issue commence today The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authorization granted by the extra general meeting on 1...

Press release Malmö, 30 September 2019 Acarix publish EU growth prospectus in connection with rights issue of up to approximately SEK 51.8 million The board of directors of Acarix AB ("Acarix" or the "Company") resolved on 25 September 2019, pursuant to the authori...

Press release  Malmö, 25 September 2019 Acarix carries out a rights issue of approximately SEK 51.8 million to finance an increased market expansion The board of directors of Acarix AB ("Acarix" or the "Company") has today, pursuant to the authorization granted by...

Press releaseMalmö August 5, 2019 Announcement from Acarix's extra general meeting The extra general meeting ("EGM") of Acarix AB ("Acarix" or the "Company") was held today on 16 August 2019 and the following resolutions were passed by the meeting...

Acarix AB (publ) publishes Interim Report, January – June 2019 Malmö, August 6, 2019 CADScor®System Included in UK guidance forruling out Coronary Artery Disease ”With CADScor®System we have a fantastic opportunity to rev...

Press release Malmö August 5, 2019 CADScor®System – Significantly more effective than current practice Acarix AB (publ) (ACARIX: FN Stockholm) today announced the publication of a meta-analysis including 2245 patients showing Acarix’s leading CADScor®System is more than three times as e...